Take heed nuc med labs. The British have come up with a smashing idea: an instrument that allows medical physicists to make sure the instruments they use to check the doses of radioactive compounds are themselves accurate.
Take heed nuc med labs. The British have come up with a smashing idea: an instrument that allows medical physicists to make sure the instruments they use to check the doses of radioactive compounds are themselves accurate.
The device, Fidelis, is a computer-controlled electrometer married to a gas-filled chamber set between two conducting electrodes. When a radioactive source is placed near the chamber, gamma rays emitted by the source ionize the gas, creating a current that can be measured by the high-resolution, high-linearity electrometer. The chamber was designed by the National Physical Laboratory, the U.K.'s national measurement institute.
Developed and brought to the market by Southern Scientific, Fidelis serves as an example of the applied technology program of NPL, which licenses government-owned technology to the private sector.
The finished product has been available for several months, but only now is the company beginning to promote its value through a marketing campaign that describes Fidelis as "the next-generation radionuclide calibrator with unsurpassed accuracy and traceability."
Many hospitals use radionuclide calibrators that need recalibrating whenever new applications or newly designed vials come along. Fidelis needs no such attention, according to Southern Scientific.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.